Adults aged more than 70 who received more prescriptions for nirmatrelvir-ritonavir did not show decreased rates of ...
Hosted on MSN38m
Millions of Americans suffer from long COVID. Why do treatments remain out of reach?Congress allocated $1.2 billion in late 2020 to study long COVID and begin to develop treatments. Nearly 90,000 adults and ...
Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback